Company Description
Cerus Corporation operates as a biomedical products company.
The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced.
It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally.
The company was incorporated in 1991 and is headquartered in Concord, California.
| Country | United States |
| Founded | 1991 |
| IPO Date | Jan 30, 1997 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 630 |
| CEO | William Greenman |
Contact Details
Address: 1220 Concord Avenue, Suite 600 Concord, California 94520 United States | |
| Phone | 925 288 6000 |
| Website | cerus.com |
Stock Details
| Ticker Symbol | CERS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001020214 |
| CUSIP Number | 157085101 |
| ISIN Number | US1570851014 |
| Employer ID | 68-0262011 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| William M. Greenman | President, Chief Executive Officer and Chairman |
| Kevin D. Green CPA | Vice President of Finance and Chief Financial Officer |
| Vivek K. Jayaraman | Chief Operating Officer |
| Chrystal N. Jensen J.D. | Chief Legal Officer, General Counsel and Secretary |
| Dr. Richard J. Benjamin MBChB, Ph.D. | Chief Medical Officer |
| Dr. Laurence M. Corash M.D. | Co-Founder and Chief Scientific Officer |
| Lainie Corten | Vice President of Global Marketing |
| Carol M. Moore | Senior Vice President of Regulatory Affairs, Quality and Clinical |
| Dr. Nina Mufti Ph.D. | Senior Vice President of Research and Development |
| Jessica Hanover Ph.D. | Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 30, 2025 | SCHEDULE 13G/A | Filing |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 9, 2025 | 8-K | Current Report |
| May 30, 2025 | SD | Form - SD |
| May 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |